Drug Trial Radar · NCT03238235
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Jan 9, 2018
Primary completion
Mar 19, 2021
Study completion Mar 19, 2021
Sponsor
- Lead sponsor
- ItalfarmacoIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objectives: Primary objective: to establish the histological effects of Givinostat versus placebo administered over 12 months. Secondary Objectives: * To establish the macroscopic muscle effects of Givinostat versus placebo administered over 12 months assessed by Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS). * To determine the other histological effects of Givinostat versus placebo administered over 12 months. * To establish the efficacy of Givinostat versus placebo administered chronically over 12 months in slowing disease progression. * To assess the safety and tolerability of Givinostat versus placebo administered chronically. * To evaluate the pharmacokinetic (PK) profile of Givinostat administered chronically in the target population. * To evaluate the impact of Givinostat versus placebo administered chronically on quality of life and activities of daily living.
Conditions
- Becker Muscular Dystrophy
Interventions
GivinostatDrug
suspension of Givinostat (10 mg/mL)
PlaceboDrug
suspension manufactured to mimic Givinostat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline to Visit 11 in Total Fibrosis (%) on Log Scale, Comparing the Histology of Muscle BiopsiesTime frame: after 12 months of treatment (at Visit 11)
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS
Milan, Italy
Leiden University Medical Center LUMC
Leiden, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.